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A m n i o t i cm e m b r a n ep r o v e dt ob ev e r ye ﬀective tool in the treatment of a number of ocular surface diseases. The amniotic
membrane, however, has to be stored before its transplantation onto the ocular surface followed by mandatory serologic control in
order to exclude the transmission of certain viruses. Therefore it is most important to study if cryopreservation of the membrane
aﬀects cell surface expression of the molecules. We measured cell surface expression of CD59, a membrane-bound complement
inhibitor on the cells of freshly prepared and cryopreserved amniotic membrane. Cells of amniotic membrane were separated
mechanically. Epithelial and mesenchymal cells were identiﬁed by the intracellular expression of nanog and the cell surface ICAM1
positivity, respectively. Multicolor ﬂow cytometric immunophenotyping was used for determination of the CD59 expression.
CellQuest-Pro software program (Becton Dickinson) was used both for measurements and analysis. CD59-positive cells could
be detected in all investigated samples and in all investigated cell types, although the expression level of CD59 diﬀered. CD59 was
expressed both on freshly prepared and frozen-stored samples. Higher level of CD59 was detected on ICAM1+ mesenchymal cells
than on nanog+ epithelial cells. Our ﬁndings indicate that amniotic membranes maintain their complement inhibiting capacity
after cryopreservation.
1.Introduction
Amniotic membrane covers the innermost layer of the
fetal extraembryonic membrane. The amniotic membrane
consists of a single layer of columnar epithelial cells, a
thick basement membrane, and a thin layer of avascu-
lar stroma. In the last 15 years the amniotic membrane
has been used widely in the ophthalmology. It proved
to be very eﬀective tool in the treatment of a number
of ocular surface diseases, such as nonhealing epithelial
defect and sterile ulcer of the cornea, alkali burn of the
eye, and surgery of cicatrizing conjunctivitis [1]. One of
the most valuable properties which makes the amniotic
membrane suitable for this is its intrinsic anti-inﬂammatory
action [1]. The mechanism of this anti-inﬂammatory,
immunosuppressive eﬀect is not completely understood.
A complement inhibitor capacity could contribute to
the anti-inﬂammatory eﬀect of the transplanted amniotic
membrane.
ComplementactivationproductsC3a,C4a,andC5awere
detected in the amniotic ﬂuid samples of normal pregnants,
suggesting that these anaphylatoxins are physiologic con-
stituentsoftheamnioticﬂuid[2–5].Theincreasedactivation
of the complement system as a consequence of microbial
invasion may lead to preterm labor [4] Therefore the
protection of extraembryonic membranes from the action of
the activated complement components of the amniotic ﬂuid
is essential [6].
CD59 is a surface-bound complement inhibitor protein;
its main role is to prevent the “self” cells from lysis by2 The Scientiﬁc World Journal
the activated complement system. It acts by preventing
the formation of the membrane attack complex at the
terminal step of the complement activation cascade. Due
to its crucial role in preventing damage to “self” cells, it
is widely expressed, found in a lot of tissues in the body,
and is present on all circulating cells [7]. The lack of CD59
has a fundamental pathogenetic role in a potentially life-
threatening disease of the blood, the paroxysmal nocturnal
hemoglobinuria, which can be treated successfully with the
complement-inhibitor eculizimab [8]. The expression of
CD59 has previously been detected both on epithelial [6, 9]
and on mesenchymal [10, 11] cells of the fresh amniotic
membrane, too.
However, because of the mandatory serologic control to
exclude the transmission of certain viruses, the amniotic
membrane has to be stored for at least 6 months before its
transplantation onto the ocular surface. Therefore our aim
was to study if cryopreservation inﬂuences the expression of
CD59 on the cells of the amniotic membrane.
2.MaterialsandMethods
2.1. Amniotic Membrane Samples. The preparation of the
amniotic membrane was performed under sterile condi-
tions according to the method of Kim and Tseng [12].
The amniotic membrane was mechanically separated from
the placenta taken from normal full-term uncomplicated
elective cesarean section. The separated amnion tissue was
thoroughly washed in phosphate-buﬀered saline that con-
tains antibiotics to cover Gram-negative and Gram-positive
bacteria and antifungal drugs. The pieces of membrane were
spread epithelial side up on nitrocellulose paper and ﬁxed
withtwo7/0vicrylsutures.Thepiecesforstoragewereplaced
in small bottles in ﬂuid containing 50% glycerol and 50%
Dulbecco’s modiﬁed Eagle Medium (DMEM, Gibco). The
tissue was stored frozen at −80◦C for 1 to 14 months.
Investigated amnion membrane samples derived from
9d i ﬀerent placentas. For the investigation of the eﬀects
of cryopreservation we detected the CD59 expression of
amniotic cells in freshly prepared membranes and from
amniotic membrane samples stored for 1 to 14 months. The
number of samples taken from a certain placenta at a certain
preservation time was 1 to 5 (Table 1).
A piece amniotic membrane of a placenta was used for
observing the eﬀect of 15 minutes freezing at −80◦C, the
cells isolated from half of the native sample and from the
frozen second half of the same sample were investigated
simultaneously.
2.2. Separation of the Cells from the Amniotic Membrane
Pieces. The separation of the amniotic membrane cells was
performed mechanically with the medimachine device (Bec-
ton Dickinson). The advantage of this mechanical separation
over the enzymatic separation is its tolerance of the cells,
that is, the proportion of cells remaining intact is high.
For the cell separation a 35µm pore size milling head was
used. The machine worked for 45 seconds. After that the cell
Table 1: Number of amniotic membrane pieces taken from the
certain placentas and worked up after diﬀerent freezing times. The
A – Gm a r k ss h o wt h e7d i ﬀerent placentas used for the experiment.
The numbers show the pieces taken from the certain placenta and
processed freshly or after the signed time long freezing.
Placenta fresh 2–4 months 5–8 months 13-14 months
A2
B2
C2 1
D5
E1 4
F4
G5
suspension was removed from the milling head with syringe
and ﬁltered through 35µm pore size Filcon ﬁlter.
2.3. Multicolor Staining of Cells for Flow Cytometry. CD59
expression of amnion membrane cells that was determined
by ﬂuorescein isothianate (FITC) conjugated monoclonal
anti-human CD59 antibody. Intracellular staining of nanog
(a transcription factor critically involved with self-renewal
of undiﬀerentiated embryonic stem cells) was used for the
identiﬁcation of epithelial cells, while cell surface ICAM1
(CD54) positivity was used for the characterization of
mesenchymal cells [13].
For the detection of CD59 expression of mesenchy-
mal cells, 105 cells were incubated with FITC-conjugated
monoclonal anti-human CD59 antibody and phycoerythrin
(Pe-) conjugated monoclonal antihuman ICAM1 (CD54)
antibody at room temperature for 20 minutes. Both anti-
bodies were manufactured by BD Biosciences (San Jose,
CA, USA). After incubation the unbound antibodies were
removed by washing with PBS and the cells were ﬁxed
by 2% paraformaldehyde (Sigma-Aldrich, St. Louis, MO,
USA) solution. For the determination of CD59 expression
of epithelial cells, the CD59 stained cells were ﬁxed by 4%
paraformaldehyde (Sigma-Aldrich, St. Louis, MO, USA),
permeabilized by 0.1% saponin solution (Sigma) and incu-
bated with Pe-conjugated anti-human nanog monoclonal
antibody. Before the measurements cells were washed with
0.1% saponin solution forremoving the unbound antibodies
and ﬁxed by 2% paraformaldehyde (Sigma-Aldrich, St.
Louis, MO, USA) solution. Optimal amounts of antibodies
were determined earlier.
2.4. Measurements. Measurements were carried out using a
FACS Calibur ﬂow cytometer (Becton Dickinson) on the
day of the staining, collecting 5 × 104 cells/tube. CellQuest-
Pro software program (Becton Dickinson) was used for
analysis. Detected curves (histograms) were separated based
on their ﬂuorescence intensity; control peak derived from
“isotype” control antibodies, while positive histogram peaks
derived from speciﬁc antibodies. Quantitative percentage of
cells with the investigated properties was calculated by theThe Scientiﬁc World Journal 3
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Figure 1: CD59 expression of amniotic cells. Count of the CD59+ cells versus the intensity of cell staining is presented. (a): fresh, (b): 1
month, (c): 4 months, (d): 14 months freezing time. The intervals signed by M1 marker mark out the CD59-positive cells. M2 and M3 show
the subgroups of less intensively and more intensively stained cells, respectively.
software after separated the histograms with markers (see
Figure 1,M 1m a r k e r ) .
2.5. Statistical Analysis. Kruskal-Wallis nonparametric anal-
ysis of variance was performed to compare the percentage of
the CD59+ cells of the freshly prepared and cryopreserved
samples.
3. Results
3.1. Eﬀect of Cryopreservation on the CD59 Expression of the
Amniotic Membranes. CD59-positive cells could be detected
in all investigated amniotic membrane samples. When
we examined the same fresh sample before and after 15
minutes freezing, diﬀerences could not been detected in the
ﬂuorescence intensities (data not shown). The percentage of
the CD59+ cells varied among both the freshly prepared and
cryopreserved (1 to 14 months) samples (46–94% and 39–
98%, resp.). There was, however, no statistically signiﬁcant
diﬀerence in the proportion of the CD59+ cells between the
fresh and preserved samples (Table 2).
The percentage of CD59+ cells was variable even among
diﬀerent pieces of the same placenta at the same preservation
time. The variation coeﬃcient of the measurement in fresh
placentas was 22.9%.
3.2. Expression of CD59 on Diﬀerent Cell Types of the Amniotic
Membranes. ThedetectedCD59histograms frequentlyshow4 The Scientiﬁc World Journal
Table 2: Rate of CD59 positive cells in amniotic membrane pieces
processed after diﬀerent freezing times. The rates are given in
percent, as mean ± standard deviation. Markedly no relation can be
discovered in the rate of CD59-positive cells and the freezing time.
Placenta fresh 2–4 months 5–8 months 13-14 months
A 62,0 ±18,7
B 88,0 ±11,2
C 96,5 ±0,5 51
D 63,0 ±14,5
E 94,0 61,7 ±15,3
F 56,1 ± 6,8
G 63,6 ±18,5
a bimodal (2 peak) distribution (Figure 1). Amniotic mem-
branes contain diﬀerent cell types, most of them are
epithelial cells and mesenchymal cells. We supposed that the
bimodal histograms were caused by the diﬀerent expression
levels of CD59 on diﬀerent amniotic cell types. Using mul-
ticolor ﬂow cytometric measurements we compared the cell
surface expression of CD59 of epithelial and mesenchymal
cells. CD59 were found to be expressed in both types of
cells. Higher level of CD59, however, could be detected on
ICAM1+ (CD54) mesenchymal cells than on the nanog+
epithelial cells (Figure 2).
4. Discussion
In the present study we examined whether the amniotic
membrane retains its complement inhibitory potential, after
storage frozen for 6 months in the form it is usually
sutured on the diseased ocular surface. We demonstrated the
presence of complement regulator CD59 on the surface of
freshly prepared and cryopreserved amniotic cells as well.
The cells of the amniotic membrane do not survive the
freezing at −80◦C, no living cells were detected with vital
staining and ultrastructural examination, and cells removed
enzymatically from cryopreserved membranes did not grow
in culture [14, 15]. However, our results show that the CD59
molecules produced originally are still present on the surface
of these cells after freezing, so they have the capability to
express its complement regulatory eﬀect.
Complement system is a powerful inﬂammatory agent,
which certainly has role in the defense of the ocular
surface.Weunderstandcomplementactivationundercertain
physiologic circumstances, like closed eye [16, 17]a n ds o m e
nonphysiologic or pathologic conditions, such as contact
lens wear [18], after keratoplasty [19] and in conjunctivitis
[20]. The elements of the complement system were detected
in the normal human cornea as well [21]. However, in state
of increased complement activation, ocular surface needs
protection. In deed, large amount of complement inhibitor
factors (CD59, DAF) was shown out on the surface of the
cornea and conjunctiva [22]. This defense mechanism may
not be enough for preserving the ocular surface integrity
in case of some conditions such as nonhealing epithelial
defect and ulcer of the cornea. The presence of CD59 in
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Figure 2: CD59 expression of epithelial and mesenchymal cells.
Count of nanog+ epithelial cells and ICAM+ mesenchymal cells
versus intensity of CD59 positivity is shown. Lower level of CD59
could be detected on the nanog+ epithelial cells than on ICAM1+
mesenchymal cells. (grey color: nanog+ epithelial cells, dark color:
ICAM+ mesenchymal cells).
the transplanted cryopreserved amniotic membrane could
supplement the autologous protection of the ocular surface.
This could contribute to the explanation of the beneﬁcial
eﬀect of the amniotic membrane in the ocular surface
diseases. As the CD59 is bounded both to the epithelial and
stromal cells of the amniotic membrane, this may contribute
to the fact that the anti-inﬂammatory eﬀect of the amniotic
membrane is independent from that it is positioned onto the
ocular surface with epithelial side up or down.
Another novel ﬁnding of our study is the diﬀerence
between the extent of CD59 expression between two types of
cells of the amniotic membrane, epithelial and mesenchymal
cells. In earlier studies CD59 expression was demonstrated
both on epithelial and mesenchymal cells, but they were
not examined in the same experiment [6, 9–11]. Using
multicolor staining method in the present study we could
compare the cell surface expression of CD59 on epithelial
cells and mesenchymal cells, in the same sample. We could
demonstrate that the mesenchymal cells express higher
amounts of CD59 on their surface than the epithelial cells.
We can conclude that the amniotic membrane derived
epithelial and mesenchymal cells express in diﬀerent extent
the complement inhibitory protein CD59 molecules on their
surface. CD59 expression could be detected both on freshly
prepared samples and also after cryopreservation, indicat-
ing that amniotic membranes maintain their complement
inhibiting ability during cryopreservation.
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